Fig. 5

PLOD3 exaggerates the CRC liver metastasis. A–C Bioluminescence on days 14 post-CT26/MC38-luciferase cell injection. Quantification of the photon flux ratio per mouse at each time point (n ≥ 5 mice per group); D, E, F Hepatic H&E staining of mouse liver with liver metastases. Weights of liver and whole body in shNC group and shPLOD3 group were measured and the results are expressed as the liver weight to body weight ratio; G Imaging of metastatic nodules in liver specimens from metastatic models established by spleen injection of CT26 cells. H IHC to detect the expression of PLOD3 in mouse liver with liver metastases; I Concentration of the mouse serum liver function markers ALT and AST on day 14 after CT26 injection (n ≥ 5 mice per group); Data are shown as the mean ± SEM (three independent experiments). *P < 0.05; **P < 0.01; ***P < 0.001)